348results about How to "Reduce efficacy" patented technology

The present invention relates to pyrazinoylguanidine compounds represented by formula (I): where at least one of R3 and R4 is a group represented by formula (A): where the other structural groups are defined herein. The present invention also includes a variety of methods of treatment using these sodium channel blockers.

The present invention relates to compounds represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.

Methods and compositions for delivering a meloxicam compound are disclosed and described. In one aspect, a method may include perorally administering to a subject a therapeutically effective amount of a meloxicam compound that provides a meloxicam plasma concentration within 1 hour which is at least about 40% of the maximum plasma concentration attained by the formulation. In another aspect, a composition may include a therapeutically effective amount of a meloxicam compound in a pharmaceutically acceptable carrier including at least one of an alkalizer or a solubilizer, with the meloxicam compound having a solubility in the carrier that is greater than about 1.0 mg / gm.

The present invention provides compound represented by formula (I):where the structural variables are defined herein. The compounds function as sodium channel blockers and may be used to treat a variety of respiratory conditions.

Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and / or treat disease, especially virus-induced diseases, are also disclosed.

A pixel driving system in an active matrix display is provided. The system includes a first sub-pixel including a first transparent area and a first drive circuit area, and a second sub-pixel including a second transparent area and a second drive circuit area, in which the first drive circuit area is electrically connected to the second transparent area so as to drive the second sub-pixel for light-emitting, and the second drive circuit area is electrically connected to the first transparent area so as to drive the first sub-pixel for light-emitting. Further, a method for driving a pixel in an active matrix display is also provided.

The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

The present application provides methods and compositions for improving the bioavailability of a lipid-containing antiviral compound, and in particular, an antiviral lipid-containing compound. In one embodiment, pharmaceutically acceptable compositions are provided that include an antiviral lipid-containing compound, or salt, ester, or prodrug thereof and one or more bioavailability enhancing compounds, such as inhibitors of cytochrome P450 enzymes.

A medication storage for storing medications while cooling down them is constituted so as to allow a medication based on prescription data to be certainly taken out. The medication storage cools down inside a storeroom for storing the medications to a predetermined temperature by a cooling unit. The medication storage, includes: a plurality of shelves rotatably provided in the storeroom; a plurality of storage partitions which are respectively constituted on each shelf and store the medications; a motor for rotating the shelves; a plurality of openings provided respectively for being arranged to correspond to each of the shelves thereby allowing only medication in any one of the storage partitions to be taken out; a plurality of doors for openably closing each opening, respectively; a plurality of lock solenoids for locking each door, respectively; and a control unit for controlling the motor and the lock solenoid. The controller permits the shelves to be rotated based on the prescription data so as to bring a predetermined storage partition to a position corresponding to the opening and then to permit the lock solenoid to be unlocked.

The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.

Prodrugs that are activated by and conjugated to a catalytic antibody conjugated to a moiety that binds to a tumor cell population are provided.

A topical insecticide is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. In one preferred embodiment of the invention, the active ingredient of the insecticide formulation is an amine derivative, having a nitro-methylene group, a nitroamino group or a cyanoamino group, which can be formulated to have low toxicity and excellent insecticidal activity. One particularly suitable insecticide is 1-{(tetrahydro-3-furanyl)methyl}-2-nitro-3-methylguanidine (dinotefuran), an aldulticide that will kill adult fleas combined with pyriproxyfen.

The invention relates to a medical fertilizer and a method for making the same. The medical fertilizer has granular shape and consists of a kernel body and at least one lagging cover, wherein, the kernel body is granular substance and the lagging cover is powder or liquid. The medical fertilizer and the method for making the same ensure that the farm chemical and the fertilizer can sufficiently work and various effective compositions are not affected; the particles such as urea are taken as kernel part and the powder or liquid farm chemical or the fertilizer, etc. are used to produce the medical fertilizer in a lagging cover way.

Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and / or treat disease, especially virus-induced diseases, are also disclosed.

A dual mode automatic device for delivery of remote ischemic preconditioning treatment includes a cuff and a controller configured to deliver a first regular treatment protocol or a second extended treatment protocol. Switching to an extended treatment protocol may be done by an operator for selected groups of patients such as elderly or patients with diabetes. Automatic determination of the best mode is also disclosed. Optimal delivery of remote ischemic preconditioning treatment in this individualized patient-specific manner provides strong ischemic protection to a greater number of patients.

The present invention relates to a formulation and method for the treatment of fungal nail infections, such as those caused by Trichophyton rubrum and / or Aspergillus niger. The formulation of the invention comprises glucose oxidase, D-glucose and hydrogen peroxide in an aqueous solution. Advantageously, the formulation of the invention provides a two-stage hydrogen peroxide release for the treatment of the fungal nail infections.

The present invention provides a flavoured product comprising four or more flavour materials having antimicrobial properties and selected from the group comprising nonanol, decanol, nonanal, decanal, amyl propionate, anethole synthetic, anisic aldehyde, basil oil, benzyl benzoate, benzyl butyrate, benzyl formate, camomile oil, cinnamic aldehyde, cis-3-hexenol, clove bud oil, damascone, ethyl acetoacetate, eucalyptus oil, ginger, isoamyl acetate, menthol laevo, methyl cinnamate, methyl salicylate, orange oil, rosemary oil, tarragon, Tea Tree oil, and peppermint oil; and one or more antimicrobial agents selected from the group comprising triclosan, pyrophosphates, zinc salts, cetylpyridinium chloride, parabens, stannous salts, sodium dodecyl sulphate, chlorhexidine, copper salts, strontium salts, peroxides and sanguinarine.

The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.

The invention discloses a foam dewatering agent. The foam dewatering agent is prepared by the following raw materials by weight percentage: 5-10% of triethylene tetramine, 10-20% of diethylenetriamine, 1-30% of oleic acid, 2-10% of glacial acetic acid, 5-15% of maleic anhydride, 5-10% of acrylic acid, 2-7% of citric acid, 5-30% of imidazoline, 5-30% of LAS, 5-10% of HCl aqueous solution with the mass percentage concentration of 20%, 5-10% of NaOH aqueous solution with the mass percentage concentration of 30% and 10-30% of water. The foam dewatering agent integrates foam dewatering, corrosion inhibiting and antiscaling functions, as one potion has the functions such as foam dewatering, corrosion inhibiting and antiscaling and the like at the same time, so that one-time filling-up can replace the traditional three-time respective filling-up, thus reducing the cost, simplifying the process without affecting the functions and prolonging the period of validity. The invention also discloses a method for preparing the foam dewatering agent.

This invention is directed to a method of preserving colloid-stabilized polymer emulsions against microbial attack and spoilage using selected cationic compounds. It is also directed to compositions containing colloid-stabilized polymer emulsions and cationic compounds that are resistant to contamination with biodeteriogenic microbes. It has been discovered that specific cationic compounds are particularly effective against biodeteriogenic microbes in preserving polymer emulsions that have been stabilized with protective colloids, such as poly(vinyl alcohol). Examples of suitable microbicidal cationic compounds are: substituted pyridinium salts, substituted guanidine salts, tetrasubstituted ammonium salts, and polymeric cationic compounds.

Polyaromatic sodium channel blockers represented by the formula:are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

Catalytic antibodies are disclosed. The catalytic antibodies are specific for prodrug compounds. The catalytic antibodies enhance cleavage of an active drug moiety from a prodrug residue, thereby activating the drug.

The invention belongs to the field of a fertilizer, in particular to a potassium humate compound fertilizer and a preparation method thereof. The potassium humate compound fertilizer is prepared by mixing urea, potassium humate, monoammonium phosphate, ammonium chloride, calcium powder and bentonite with magnesium sulfate, zinc sulfate and medium / trace elements. The potassium humate compound fertilizer granulated by using a steam drum physical agglomeration method and the preparation method of the compound fertilizer have the advantages that the prepared potassium humate compound fertilizer has large particle size and high strength and does not agglomerate; the capabilities of water and fertility retention, heat preservation and ventilation of the soil are enhanced; the soil structure is improved; the soil fertility is increased; the problems of reduced soil fertility, environmental pollution, soil hardening, nutrition unbalance and stress resistance of crops are solved; the utilization rate of the fertilizer is improved; the defects of low fertilizer efficiency, insufficient nutrition utilization, overproof pesticide residue, severe nitrate accumulation and heavy metal pollution are overcome; the sustained-release effect against pesticide is realized; the agroecological environment is protected; and the efficiency, yield and crop quality are improved.

The present application discloses methods for treating patients with a dysfunction of the ion channels of the heart suffering from one or more cardiovascular diseases to reduce the proarrhythmic effect of drugs and / or conditions that reduce or inhibit IKr.

The invention relates to a nutritional supplement with functions of oxidation resistance and fatigue resistance, which is prepared from active ingredients and auxiliary materials such as multiple vitamins, mineral substances, siberian ginseng extracts, astragalus mongholicus extracts, medlar extracts, grape seed extracts and the like. The active ingredients in the supplement have a special proportion; the nutritional supplement can achieve the same effects of oxidation resistance and fatigue resistance by using a dose of traditional Chinese medical extracts smaller than the conventional dose;and the nutritional supplement has the characteristics of low potential toxicity, low production cost, obvious treatment effect and low price, thereby being suitable for long-time use.

An orally-applied ranolazine hydrochloride for treating cardiovascular disease is prepared from ranolazine hydrochloride, diluent, adhesive, disintegrant, antisticking agent and lubricant through adding wetting agent, preparing soft material, granulating and drying.

The high efficiency corrosion and scale inhibitor consists of polyhydrolic alcohol phosphate ester 30-40 wt%, zinc sulfate 15-30 wt%, acrylic acid, acrylate and sulfonate copolymer 5-10 wt%, except water. The high efficiency corrosion and scale inhibitor is used as scale inhibitor and corrosion inhibitor in circular cooling water of oil refinery, chemical plant, chemical fertilizer plant, air conditioning system, heat exchanger of copper, etc. and is especially suitable for use in water flooding recovery. The outstanding advantages of the present invention include operating capacity in relatively high concentration of total soluble solid content up to 30 g / L in cooling water, and high corrosion and scale inhibiting effect even if in oil containing sludge water condition.